

26 October 2022

## New Biologic Medications within Dermatology

Could you please tell me how many patients were treated in September 2022 (or latest available month) by the Dermatology department with the following drugs:

• Abrocitinib (Cibinqo)	0
• Baricitinib (Olmiant)	<5
• Bimekizumab (Bimzelx)	<5
• Brodalumab (Kyntheum)	0
• Dupilumab (Dupixent)	108
• Ixekizumab (Taltz)	47
• Risankizumab (Skyrizi)	65
• Guselkumab (Tremfya)	85
• Secukinumab (Cosentyx)	38
• Tildrakizumab (Ilumetri)	6
• Tralokinumab (Adtralza)	0
• Upadacitinib (Rinvoq)	16
• Ustekinumab (Stelara)	80

**Use of < 5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.